Abstract Library

#2693 The Distinctive Character of Micro-Vasculature and Immune Cell Infiltration in Cystic Pancreatic Neuroendocrine Tumors

Introduction: Hypervascularity is main character of pancreatic neuroendocrine tumors (PanNETs), cystic PanNET (CPanNET) are unique type of PanNETs for which the microenvironment remains unknown.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Gao H,

Keywords: pancreatic neuroendocrine tumors, cystic, microvascular density, microvascular integrity, tumor-associated macrophage,

#2261 Mechanisms of Main Pancreatic Duct Dilatation in Pancreatic Neuroendocrine Tumors (PanNETs): Radiopathologic Correlation

Introduction: Main pancreatic duct (MPD) dilatation, a frequent observation in cases with adenocarcinoma can also be observed in patients with PanNET.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Ronot M

Authors: Ronot M, Cros J, Faccinetto A, de Mestier L, Hentic O,

Keywords: Sclerozing PanNET, MRI, Main duct dilatation,

#1850 Influence of VEGF Splicing on Microvessel Density and Architecture in Pancreatic Neuroendocrine Tumours

Introduction: Hypoxia in human tumours is associated with a poor prognosis and is characterized by the stabilization of HIF1α, upregulation of VEGF, and a high microvessel density (MVD). Interestingly, although pancreatic neuroendocrine tumours (pNETS) showing hypoxia signalling also have a poor prognosis, they paradoxically display a low MVD. We hypothesized that this paradoxon might be explained by alternative splicing of VEGF.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Schmitt A

Authors: Marinoni I, Naim S, Centeno I, Perren A, Schmitt A,

Keywords: pNET, VEGF,

#756 Evaluation of VEGF, VEGFR 1-2-3 and Endocan/ESM-1 Expression in Gastroenteropancreatic Neuroendocrine Tumors and Correlation with Ki-67 Labeling and Prognosis

Introduction: Angiogenesis is recognized to play a critical role in progressive tumor growth and spreading and its inhibition is a valuable approach to cancer treatment. Markers of angiogenesis include assessment of microvessel density on tissue sections (often evaluated with antibodies against pan-endothelial antigens, such as CD34) and expression of vascular endothelial growth factor (VEGF) and its receptors (VEGFR 1-2-3). Endocan, also called endothelial cell specific molecule-1 (ESM-1), has been shown to be expressed by endothelial tumor cells and especially by tip cells during angiogenesis. Endocan is highly up-regulated by pro-angiogenic molecules, such as VEGF. Recently, Endocan has been identified to be one of the molecules involved in the switch from dormant to fast-growing tumors. Among endocrine tumors, Endocan expression has been evaluated only in pituitary adenomas: a positive association between endothelial Endocan expression and recurrence risk, tumor size, tumoral invasion and average mitosis count has been demonstrated. In contrast, there was no association between endothelial Endocan expression and the Ki-67 labeling index

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Lugli F, Iacovazzo D, Fusco A, Lanza P, Rindi G,

Keywords: endocan, angiogenesis, vegf,

#180 Microvessel Density and Prognosis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETS)

Introduction: The role of anti-angiogenic agents in GEP-NETS remains to be established. CD105 (Endoglin) identifies the TGF-ß1 receptor which is expressed on endothelial cells involved in tumor angiogenesis.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Soares C, Bettencourt H, Preto J, Soares P, Pinto-de-Sousa J,

Keywords: gastroenteropancreatic neuroendocrine tumors, angiogenesis, microvessel density, CD105, Endoglin,